WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Firm” or “Spyre”), a clinical-stage biotechnology firm pioneering long-acting antibodies and antibody mixtures to redefine the usual of take care of inflammatory bowel illness and rheumatic illnesses, as we speak introduced that Spyre’s unbiased Compensation Committee of the Board of Administrators authorized the grant of inventory choices to buy an mixture of 30,200 shares of widespread inventory of Spyre to 5 non-executive staff as fairness inducement awards underneath the Spyre Therapeutics, Inc. 2018 Fairness Inducement Plan, as amended (the “2018 Plan”). The inventory choices had been authorized on February 2, 2026 and had been materials to every worker’s acceptance of employment with Spyre, in accordance with Nasdaq Itemizing Rule 5635(c)(4).
The inventory choices had been granted with a 10-year time period and an train value equal to $32.75, the closing value per share of Spyre’s widespread inventory as reported by Nasdaq on February 2, 2026. The choices granted to the staff shall vest and turn out to be exercisable as to one-fourth (1/4th) of the shares topic to the respective choices on the primary anniversary of the worker’s begin date, and one-forty-eighth (1/forty eighth) of the shares topic to the respective choices shall vest and turn out to be exercisable month-to-month thereafter, in every case, topic to steady service with Spyre via the relevant vesting dates. The inventory choices are topic to the phrases of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology firm pioneering long-acting antibodies and antibody mixtures to redefine the usual of take care of inflammatory bowel illness (“IBD”) and rheumatic illnesses. Spyre’s pipeline consists of investigational prolonged half-life antibodies focusing on α4β7, TL1A, and IL-23.
For extra info, please go to http://spyre.com.
For Buyers :
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com
Source link
#Spyre #Therapeutics #Publicizes #Grants #Inducement #Awards
